Drugs / BMS-986331
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04444050 | Jun 2020 → May 2021 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986331 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04444050 ↗ |
| Route | Oral | “oral doses of BMS-986331” NCT04444050 ↗ |